Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Athenex, a US-China Pharma, Lands $225 Million Investment

publication date: Feb 15, 2016
Athenex, a US-China oncology company, announced that New York State will invest $225 million to build a large manufacturing facility for the company in the western part of the state. Athenex agreed to contribute $1.6 billion over ten years in wages, materials and supplies. In October, Athenex and Chongqing, China struck a similar deal in which the municipal government will build two factories for the company. Athenex will make APIs for global markets and oncology drugs for China in the plants, and it will be responsible for equipping them. Also in 2015, Athenex acquired Comprehensive Drug Enterprises, which included a Hong Kong R&D operation and a manufacturing facility in the Fengdu district of Chongqing. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital